## Abstract Malignant gliomas are relatively uncommon but lethal cancers. Despite recent research efforts in cancer therapy, the prognosis of patients with malignant gliomas has remained dismal. Understanding the molecular pathogenesis of glioma may lead to a rational development of new therapies.
β¦ LIBER β¦
EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma
β Scribed by Bryan D. Choi; Gary E. Archer; Duane A. Mitchell; Amy B. Heimberger; Roger E. McLendon; Darell D. Bigner; John H. Sampson
- Book ID
- 111404670
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 623 KB
- Volume
- 19
- Category
- Article
- ISSN
- 1015-6305
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Molecularly targeted therapy for maligna
β
Sith Sathornsumetee; David A. Reardon; Annick Desjardins; Jennifer A. Quinn; Jam
π
Article
π
2007
π
John Wiley and Sons
π
English
β 473 KB
π 1 views
Targeted molecular therapy of malignant
β
Santosh Kesari; Naren Ramakrishna; Claire Sauvageot; Charles D. Stiles; Patrick
π
Article
π
2005
π
Springer
π
English
β 933 KB
Targeted molecular therapy of malignant
β
Santosh Kesari; Naren Ramakrishna; Claire Sauvageot; Charles D. Stiles; Patrick
π
Article
π
2006
π
Current Science Inc.
π
English
β 359 KB
Targeted molecular therapy for malignant
β
L. Burt Nabors
π
Article
π
2004
π
Springer
π
English
β 251 KB
Targeted therapies on the horizon for ma
β
Silvia Hofer; Roger Stupp
π
Article
π
2010
π
Springer-Verlag
π
English
β 344 KB
Mitochondria-bound hexokinase as target
β
StΓ©phane Oudard; Florence Poirson; Laurent Miccoli; Yveline Bourgeois; Anne Vass
π
Article
π
1995
π
John Wiley and Sons
π
French
β 806 KB
Hexokinase plays an important role in glucose-utilizing tissues like normal brain and cancers. In these tissues, hexokinase (HK) is mainly bound to mitochondria (mHK). Our objectives were to evaluate total HK (tHK) activity and mHK fraction in gliomas and to determine whether mHK binding could be ta